Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Edgewise Therapeutics, retaining the price target of $42.00.Joseph Pantginis has given his Buy rating due to a combination of factors that underscore both the clinical and strategic strength of Edgewise Therapeutics. He highlights that EDG-7500’s updated Phase 2 CIRRUS-HCM data show sustained clinical benefit across key hypertrophic cardiomyopathy measures, including biomarkers, functional status, symptoms, and quality of life, while maintaining stable left ventricular ejection fraction and avoiding clinically meaningful declines. The absence of treatment-related atrial fibrillation in the lower-dose cohorts, combined with preserved efficacy, supports a compelling risk-benefit profile and suggests dose flexibility as the program advances. In addition, the ongoing Part D of CIRRUS-HCM, which is testing a range of doses and biomarker-guided optimization, is expected to generate a robust exposure–response data set to fine-tune the upcoming pivotal trial. Pantginis also emphasizes that the company is on track to initiate a Phase 3 trial for EDG-7500 by year-end 2026, which he views as an important value-creating catalyst. Beyond EDG-7500, he maintains a constructive stance on the GRAND CANYON program, citing prior sevasemten data that showed favorable separation on functional outcome curves versus Becker muscular dystrophy natural history, reinforcing confidence in forthcoming results by the end of 2026. He further interprets the advancement of additional pipeline assets, such as EDG-15400, as evidence of the company’s productive R&D engine and its ability to broaden its addressable market. Taken together, the differentiated safety/efficacy profile of EDG-7500, clear late-stage development path, and expanding pipeline lead him to support a Buy rating on EWTX shares.In another report released today, Truist Financial also reiterated a Buy rating on the stock with a $46.00 price target.